James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.
Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body...
Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor ...
Mary L. Disis, MD, of the University of Washington, discusses innate and adaptive immune system cells, T cells as key to mediating antitumor immunity, and the mechanisms by which c...
Roy S. Herbst, MD, PhD, of the Yale School of Medicine, summarizes a session that included discussion of the mechanisms of immunotherapies, biomarkers for activity of these agents,...
Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification an...